Published within
|«
«
|
1
|
2
|
3
|
4
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
A new article in the Journal of the American Medical Association reveals that interleukin-12/23 inhibitors such as Abbott's Ozespa do not raise cardiovascular risks in psoriasis patients compared to placebo or TNF inhibitors. Abbott will welcome the news, but Datamonitor believes that while Ozespa is a key contender if resubmitted for approval, hurdles remain as more extensive data are needed.
Published By Datamonitor
|
24 Aug 2011 |
|
CommentWire
|
Top-line Phase III clinical trial data of Botox for the prophylactic treatment of chronic migraine showed a statistically significant decrease in the number of headache days at 24 weeks. Depending on full data results expected in mid-2009, Botox could become the first approved treatment for this debilitating and largely underserved condition.
Published By Datamonitor
|
12 Sep 2008 |
|
CommentWire
|
In an effort to generate interest from potential partners in its investigational myasthenia gravis agent, EN101, Amarin has announced positive final efficacy data from an exploratory Phase IIa study. Although these promising data support a symptomatic effect, greater value could be expected if immunosuppressant activity is also demonstrated in later trials.
Published By Datamonitor
|
11 Jun 2009 |
|
Expert View
|
In May 2009, Datamonitor attended the annual American Psychiatric Association meeting in San Francisco. At the conference, AstraZeneca and Pfizer presented data for two high-profile products for which they hope to gain label expansions into generalized anxiety disorder. However, both companies have found pursuing this expansion to be challenging.
Published By Datamonitor
|
29 May 2009 |
|
Expert View
|
The annual meeting of the American Psychiatric Association is the year's largest psychiatry event. This year's conference in San Francisco indicated that long-acting depot versions of atypical antipsychotics continue to prove useful tools in the treatment of schizophrenia. In addition, new potential market entrants reported mixed data from new oral antipsychotics.
Published By Datamonitor
|
29 May 2009 |
|
Expert View
|
At the recent meeting of the American Psychiatric Association, Forest/Gedeon Richter and Lundbeck attracted attention following the presentation of positive data for two novel drugs in bipolar disorder and depression, respectively. Given that both these indications are highly competitive and genericized markets, the companies are already seeking to differentiate their respective products.
Published By Datamonitor
|
29 May 2009 |
|
Expert View
|
At the American Psychiatric Association's annual meeting, British pharmaceutical firm Shire presented data on its diverse attention deficit hyperactivity disorder portfolio, covering three key products. Through continued astute portfolio management, Datamonitor forecasts Shire to remain the market leader with a 40% share of the ADHD sector by 2017.
Published By Datamonitor
|
29 May 2009 |
|
Expert View
|
Datamonitor attended this year's American Society of Hematology annual meeting in New Orleans, focusing on key developments in hematological malignancies. While recent trial results are likely to support new applications for Velcade and Revlimid in first-line multiple myeloma, the data also suggest that the future of treatment may actually be a combination of the two.
Published By Datamonitor
|
11 Dec 2009 |
|
Expert View
|
At this year's American Society of Hematology meeting, researchers presented results from a Phase III study comparing Tasigna and Gleevec in newly diagnosed chronic myeloid leukemia. While Tasigna's efficacy is impressive, it is unlikely that the drug will achieve the same market penetration as Gleevec in newly diagnosed patients due to fierce competition from Sprycel.
Published By Datamonitor
|
11 Dec 2009 |
|
CommentWire
|
The continuing development of Zactima in non-small-cell lung cancer will be welcome news for AstraZeneca, following the recent failure of Recentin in the same indication. Success in this indication now hinges on whether Zactima's mechanism of action can translate into notable clinical benefit.
Published By Datamonitor
|
14 Mar 2008 |
|
|«
«
|
1
|
2
|
3
|
4
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.